Patients who rely on immunoglobulin (Ig) to treat their condition need sustained and continued access to their Ig therapies.
Immunodeficiency UK supports the following IPOPI key statements concerning access to immunoglobulin therapies for people with primary immunodeficiency (PID).
We would like to particularly draw attention to the following:
- Ig therapies should be prioritised and ring-fenced for PIDs since there are clear life-threatening indications, proven efficacy, and no alternative treatments available
- A process for Ig demand management should be adopted to ensure appropriate access for all patients who need Ig treatment.
- Demand management plans need to be implemented to ensure continuity of supply to all patients with who need Ig, particularly in times of product shortage (whether lack of plasma collection or manufacturing issues, contamination incidents, or other reasons).
- National decision-making around the supply of Ig therapies should always include the expertise of clinical experts and patient representatives in a collaborative way.
In times of shortages or supply tensions:
- Stable PID patients should not have their therapy reduced, altered in terms of dose or cycle. Changes, including brand changes, should be driven on clinical grounds only.
- Newly diagnosed PID patients should not be denied access to appropriate treatment.
- Health systems should ensure the plurality of Ig suppliers and a wide range of both intravenous Ig (IVIg) and subcutaneous immunoglobulin (SCIg) therapies is the way to ensure stable and sustainable treatment.
- Health systems should diversify the supply of SCIg and IVIg. Ensuring a range of Ig therapies is available for optimal individualised care.
Posted 30th April 2021